As part of its Delivering Hope™ program, Bristol-Myers Squibb has awarded four new grants totaling $1.69 million to improve prevention, care, and support of HBV and HCV in China and India. China and India account for almost 50% of all hepatitis B (HBV) and hepatitis C (HCV) infections worldwide, having an estimated 123 million people chronically infected with HBV and 59 million people chronically infected with HCV.

The recipients of the new grants are long-term partners of Delivering Hope™. Organizations and projects receiving support are China Foundation for Hepatitis Prevention and Control, HOPE Initiative, Liver Foundation West Bengal, and a coalition that includes the United Way of Mumbai, the National Liver Foundation, and AmeriCares India.

China Foundation for Hepatitis Prevention and Control will receive $401,687 over three years to create a HBV and HCV patient empowerment model to enhance patients’ ability to manage their disease. HOPE Initiative will receive $355,694 over three years to create a HCV patient support network and conduct studies to explore the effectiveness of blood donation and transfusion regulations. Liver Foundation West Bengal will receive $539,035 to develop comprehensive interventions for patients who have HBV or HCV and comorbid non-communicable diseases such as type 2 diabetes, hypertension, cardiovascular disease, and fatty liver disease. United Way of Mumbai, the National Liver Foundation and AmeriCares India will receive $389,464 over two years for efforts targeted at the prevention and care of HBV and HCV in pregnant women and women of childbearing age.

Previous articleGone Today, Hair Tomorrow
Next articleNew Luciferins